Pulse Biosciences (NASDAQ:PLSE) Trading Up 13.6% – Still a Buy?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) traded up 13.6% during trading on Thursday . The stock traded as high as $27.58 and last traded at $28.39. 82,893 shares traded hands during trading, a decline of 74% from the average session volume of 324,168 shares. The stock had previously closed at $24.99.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Canaccord Genuity Group initiated coverage on shares of Pulse Biosciences in a research report on Thursday. They set a “buy” rating and a $32.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 20th. Mizuho set a $30.00 price target on Pulse Biosciences in a research note on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pulse Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $30.67.

Pulse Biosciences Stock Up 10.7%

The company’s fifty day moving average is $22.53 and its 200 day moving average is $18.65. The stock has a market cap of $1.92 billion, a PE ratio of -25.17 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.25 million. Equities analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Buying and Selling

In other news, Director Robert W. Duggan bought 660,233 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the acquisition, the director directly owned 48,211,433 shares in the company, valued at $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Paul A. Laviolette bought 15,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $19.69 per share, for a total transaction of $295,350.00. Following the completion of the acquisition, the chief executive officer owned 15,000 shares in the company, valued at approximately $295,350. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Pulse Biosciences by 8.2% during the 1st quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after acquiring an additional 65,884 shares during the period. Cetera Investment Advisers acquired a new position in shares of Pulse Biosciences during the 1st quarter valued at $387,000. Tudor Investment Corp ET AL acquired a new position in shares of Pulse Biosciences during the 4th quarter valued at $382,000. Inspire Investing LLC lifted its position in shares of Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock valued at $469,000 after acquiring an additional 8,561 shares during the period. Finally, California State Teachers Retirement System lifted its position in shares of Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock valued at $291,000 after acquiring an additional 3,991 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.